Patient P-03123
Therapy response
Stable
Tolerance
Stable
GI state
Improving
Inflammatory state
Improving
Nutritional resilience
Unstable
Discontinuation risk
61%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 ONX-7 started — Baseline state S14
- Day 39 NP-02 recommended — Dietary Support Protocol NP-02
- Day 40 Patient accepted — Started NP-02 in the companion
- Day 50 No meaningful change — Dietary Support Protocol NP-02
- Day 55 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 63 GI-04 recommended — GI Support Protocol GI-04
- Day 64 Patient accepted — Started GI-04 in the companion
- Day 72 GI symptom burden −29% vs expected — GI Support Protocol GI-04
- Day 78 Tolerance state changed — Unstable → Improving
What changed?
Trajectory began diverging from predicted response on Day 55.
Primary contributors, last 14 days
- GI instability-13
- Treatment adherence+7
- Inflammatory activity-4
What helped?
- Dietary Support Protocol NP-02Day 39Result: no meaningful change
- GI Support Protocol GI-04Day 63Result: symptom burden −29%
LIFE OS recommendation
Dosing / Timing Recommendation DT-01
68%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 82% showed improvement
- median effect visible after 5 days
Daily trackers
Molecule settingsThe trackers this program marks as important, last 14 days vs the 14 before.
Energy level
Daily log3.8/10
stable · +0.0 vs previous 14 d
Stress level
Daily log4.9/10
stable · +0.2 vs previous 14 d
Pessimism score
Daily log4.6/10
stable · +0.1 vs previous 14 d
Sleep quality
Wearable39.4/100
stable · -0.9 vs previous 14 d
Libido
Daily log3.6/10
stable · -0.1 vs previous 14 d
HRV
Wearable47.4 ms
worsening · -3.1 vs previous 14 d
Toxicity
Blood42.2/100
improving · -2.4 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →Heading towards restoration · 39 from the failing basin, 48 from restoration.
Would help
- ME-01 Monitoring Escalation100% improved among 11 similar · onset 3 d · confidence 69%
- DT-01 Dosing / Timing Recommendation82% improved among 11 similar · onset 5 d · confidence 69%
- SC-12 Supportive Compound89% improved among 9 similar · onset 6 d · confidence 69%
- More proteinGI -3 next day on high-intake days · n 24
Would not help
- NP-02 Dietary Support Protocolalready tried, no meaningful change
- AD-05 Adherence Supportonly 30% improved among 10 similar
- Keep fat lowGI +3 next day on high-intake days · n 18
- Keep histamine lowGI +3 next day on high-intake days · n 22
- Keep lactose lowGI +2.4 next day on high-intake days · n 19
State influencers · digestive
Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.
- Dietary fat load+3detractor · 95%
- Histamine load+3detractor · 95%
- Protein-3supporter · 95%
- Lactose+2.4detractor · 77%
- Caffeine+0.9no signal · 25%
- Alcohol-0.5no signal · 15%
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 39/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
- Inflammatory signalling ↓50
- DNAIL6 -174 variant raises baseline inflammatory tone
- BloodInflammatory load index 50
- Mucosal barrier integrity ↓30
- DNAFUT2 non-secretor lowers mucosal fucosylation
- Autonomic recovery ↓25
- WearableResting HR 79 bpm
- Drug metabolism and exposure ↑20
- BloodToxicity index 42
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- IL6 -174 G/CHigher inflammatory tone
- CYP2D6 Normal metabolizerExpected exposure
Microbiome
Shannon diversity 2.8 · butyrate capacity 39/100
- Akkermansia muciniphilaNormal
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisNormal
- Bifidobacterium longumNormal
- EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 42 ms
- Sleep
- 7.1 h
- Steps
- 4,601
- Resting HR
- 80 bpm
Daily log: GI score 45, nutritional resilience 40, adherence 50.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- A 15-minute walk after lunch
- Keep the sleep window steady
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-03105 | 24% | S12 | AD-05 | no change | 60 |
| P-03204 | 24% | S16 | AD-05 | improved | 48 |
| P-03111 | 23% | S07 | AD-05 | no change | 48 |
| P-03351 | 23% | S07 | AD-05 | no change | 51 |
| P-03482 | 23% | S05 | AD-05 | no change | 67 |
| P-03034 | 22% | S14 | AD-05 | no change | 30 |
| P-03424 | 22% | S12 | AD-05 | improved | 41 |
| P-03158 | 21% | S17 | AD-05 | no change | 37 |
| P-03369 | 21% | S18 | AD-05 | no change | 37 |
| P-03380 | 21% | S16 | AD-05 | improved | 34 |
| P-03277 | 22% | S14 | BR-03 | improved | 41 |
| P-03357 | 37% | S02 | CR-01 | improved | 50 |